Clinical Trial Update: A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer [Phase 4]

View source ↗

Summary

Amgen conducted a Phase 4 trial of an investigational medication for severe primary hyperparathyroidism and parathyroid neoplasms; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism
• Parathyroid Neoplasms

Drugs mentioned

• Investigational medication

Snippet

Sponsor: Amgen | Conditions: Hyperparathyroidism, Parathyroid Neoplasms | Phase 4 | Status: COMPLETED